Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy

Obiageli Ezewuiro, Tatyana A. Grushko, Masha Kocherginsky, Mohammed Habis, Jean A. Hurteau, Kathryn A. Mills, Jessica Hunn, Olufunmilayo I. Olopade, Gini F. Fleming, Iris L. Romero

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

There is increasing evidence that metformin, a commonly used treatment for diabetes, might have the potential to be repurposed as an economical and safe cancer therapeutic. The aim of this study was to determine whether stage III-IV or recurrent endometrial cancer patients who are using metformin during treatment with chemotherapy have improved survival. To test this we analyzed a retrospective cohort of subjects at two independent institutions who received chemotherapy for stage III-IV or recurrent endometrial cancer from 1992 to 2011. Diagnosis of diabetes, metformin use, demographics, endometrial cancer clinicopathologic parameters, and survival duration were abstracted. The primary outcome was overall survival. The final cohort included 349 patients, 31 (8.9%) had diabetes and used metformin, 28 (8.0%) had diabetes but did not use metformin, and 291 (83.4%) did not have diabetes. The results demonstrate that the median overall survival was 45.6 months for patients with diabetes who used metformin compared to 12.5 months for patients with diabetes who did not use metformin and 28.5 months for patients without diabetes (log-rank test comparing the three groups P = 0.006). In a model adjusted for confounders, the difference in survival between the three groups remained statistically significant (P = 0.023). The improvement in survival among metformin users was not explained by better baseline health status or more aggressive use of chemotherapy. Overall, the findings in this retrospective cohort of endometrial cancer patients with stage III-IV or recurrent disease treated with chemotherapy indicate that patients with diabetes who were concurrently treated with metformin survived longer than patients with diabetes who did not use metformin.

Original languageEnglish (US)
Article numbere0147145
JournalPloS one
Volume11
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

metformin
Chemotherapy
Metformin
Endometrial Neoplasms
Medical problems
drug therapy
diabetes
Drug Therapy
neoplasms
Survival
health status
Health Status
Therapeutics
demographic statistics
testing
Demography
Health

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Ezewuiro, O., Grushko, T. A., Kocherginsky, M., Habis, M., Hurteau, J. A., Mills, K. A., ... Romero, I. L. (2016). Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy. PloS one, 11(1), [e0147145]. https://doi.org/10.1371/journal.pone.0147145
Ezewuiro, Obiageli ; Grushko, Tatyana A. ; Kocherginsky, Masha ; Habis, Mohammed ; Hurteau, Jean A. ; Mills, Kathryn A. ; Hunn, Jessica ; Olopade, Olufunmilayo I. ; Fleming, Gini F. ; Romero, Iris L. / Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy. In: PloS one. 2016 ; Vol. 11, No. 1.
@article{f8f68163e4e44d51a40bea088dc666eb,
title = "Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy",
abstract = "There is increasing evidence that metformin, a commonly used treatment for diabetes, might have the potential to be repurposed as an economical and safe cancer therapeutic. The aim of this study was to determine whether stage III-IV or recurrent endometrial cancer patients who are using metformin during treatment with chemotherapy have improved survival. To test this we analyzed a retrospective cohort of subjects at two independent institutions who received chemotherapy for stage III-IV or recurrent endometrial cancer from 1992 to 2011. Diagnosis of diabetes, metformin use, demographics, endometrial cancer clinicopathologic parameters, and survival duration were abstracted. The primary outcome was overall survival. The final cohort included 349 patients, 31 (8.9{\%}) had diabetes and used metformin, 28 (8.0{\%}) had diabetes but did not use metformin, and 291 (83.4{\%}) did not have diabetes. The results demonstrate that the median overall survival was 45.6 months for patients with diabetes who used metformin compared to 12.5 months for patients with diabetes who did not use metformin and 28.5 months for patients without diabetes (log-rank test comparing the three groups P = 0.006). In a model adjusted for confounders, the difference in survival between the three groups remained statistically significant (P = 0.023). The improvement in survival among metformin users was not explained by better baseline health status or more aggressive use of chemotherapy. Overall, the findings in this retrospective cohort of endometrial cancer patients with stage III-IV or recurrent disease treated with chemotherapy indicate that patients with diabetes who were concurrently treated with metformin survived longer than patients with diabetes who did not use metformin.",
author = "Obiageli Ezewuiro and Grushko, {Tatyana A.} and Masha Kocherginsky and Mohammed Habis and Hurteau, {Jean A.} and Mills, {Kathryn A.} and Jessica Hunn and Olopade, {Olufunmilayo I.} and Fleming, {Gini F.} and Romero, {Iris L.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0147145",
language = "English (US)",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

Ezewuiro, O, Grushko, TA, Kocherginsky, M, Habis, M, Hurteau, JA, Mills, KA, Hunn, J, Olopade, OI, Fleming, GF & Romero, IL 2016, 'Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy', PloS one, vol. 11, no. 1, e0147145. https://doi.org/10.1371/journal.pone.0147145

Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy. / Ezewuiro, Obiageli; Grushko, Tatyana A.; Kocherginsky, Masha; Habis, Mohammed; Hurteau, Jean A.; Mills, Kathryn A.; Hunn, Jessica; Olopade, Olufunmilayo I.; Fleming, Gini F.; Romero, Iris L.

In: PloS one, Vol. 11, No. 1, e0147145, 01.01.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy

AU - Ezewuiro, Obiageli

AU - Grushko, Tatyana A.

AU - Kocherginsky, Masha

AU - Habis, Mohammed

AU - Hurteau, Jean A.

AU - Mills, Kathryn A.

AU - Hunn, Jessica

AU - Olopade, Olufunmilayo I.

AU - Fleming, Gini F.

AU - Romero, Iris L.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - There is increasing evidence that metformin, a commonly used treatment for diabetes, might have the potential to be repurposed as an economical and safe cancer therapeutic. The aim of this study was to determine whether stage III-IV or recurrent endometrial cancer patients who are using metformin during treatment with chemotherapy have improved survival. To test this we analyzed a retrospective cohort of subjects at two independent institutions who received chemotherapy for stage III-IV or recurrent endometrial cancer from 1992 to 2011. Diagnosis of diabetes, metformin use, demographics, endometrial cancer clinicopathologic parameters, and survival duration were abstracted. The primary outcome was overall survival. The final cohort included 349 patients, 31 (8.9%) had diabetes and used metformin, 28 (8.0%) had diabetes but did not use metformin, and 291 (83.4%) did not have diabetes. The results demonstrate that the median overall survival was 45.6 months for patients with diabetes who used metformin compared to 12.5 months for patients with diabetes who did not use metformin and 28.5 months for patients without diabetes (log-rank test comparing the three groups P = 0.006). In a model adjusted for confounders, the difference in survival between the three groups remained statistically significant (P = 0.023). The improvement in survival among metformin users was not explained by better baseline health status or more aggressive use of chemotherapy. Overall, the findings in this retrospective cohort of endometrial cancer patients with stage III-IV or recurrent disease treated with chemotherapy indicate that patients with diabetes who were concurrently treated with metformin survived longer than patients with diabetes who did not use metformin.

AB - There is increasing evidence that metformin, a commonly used treatment for diabetes, might have the potential to be repurposed as an economical and safe cancer therapeutic. The aim of this study was to determine whether stage III-IV or recurrent endometrial cancer patients who are using metformin during treatment with chemotherapy have improved survival. To test this we analyzed a retrospective cohort of subjects at two independent institutions who received chemotherapy for stage III-IV or recurrent endometrial cancer from 1992 to 2011. Diagnosis of diabetes, metformin use, demographics, endometrial cancer clinicopathologic parameters, and survival duration were abstracted. The primary outcome was overall survival. The final cohort included 349 patients, 31 (8.9%) had diabetes and used metformin, 28 (8.0%) had diabetes but did not use metformin, and 291 (83.4%) did not have diabetes. The results demonstrate that the median overall survival was 45.6 months for patients with diabetes who used metformin compared to 12.5 months for patients with diabetes who did not use metformin and 28.5 months for patients without diabetes (log-rank test comparing the three groups P = 0.006). In a model adjusted for confounders, the difference in survival between the three groups remained statistically significant (P = 0.023). The improvement in survival among metformin users was not explained by better baseline health status or more aggressive use of chemotherapy. Overall, the findings in this retrospective cohort of endometrial cancer patients with stage III-IV or recurrent disease treated with chemotherapy indicate that patients with diabetes who were concurrently treated with metformin survived longer than patients with diabetes who did not use metformin.

UR - http://www.scopus.com/inward/record.url?scp=84958213162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958213162&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0147145

DO - 10.1371/journal.pone.0147145

M3 - Article

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e0147145

ER -